Evidence map›Paper›PMID 29707618›Full record

ArticleTransplantation direct2018

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission.

Robert A Mitchell, Trana Hussaini, Alan H Yau, Mel Krajden, Alissa J Wright, Charles H Scudamore, Vladimir Marquez Azalgara, Siegfried R Erb, Eric M Yoshida

Open access · goldAbstract read
In one paragraph

Article in Transplantation direct, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Robert A MitchellDivision of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
Trana HussainiFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Alan H YauDivision of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
Mel KrajdenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Alissa J WrightDivision of Infectious Diseases, University of British Columbia, Vancouver, BC, Canada.
Charles H ScudamoreDivision of General Surgery, University of British Columbia, Vancouver, BC, Canada.
Vladimir Marquez AzalgaraDivision of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
Siegfried R ErbDivision of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
Eric M YoshidaDivision of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe goal of treating chronic hepatitis C virus (HCV) infection is sustained virologic response (SVR). There is concern that despite achieving SVR, replication-competent HCV may be sequestered at low levels within the liver and could theoretically reactivate with immunosuppression. We report transplantation of a HCV-seropositive liver donor, who achieved SVR, into a seronegative patient without HCV reactivation despite profound immunosuppression.

methodRetrospective chart review.

resultsWe present a 21-year-old male who was HCV seronegative and received a liver transplant from a donor who had been treated for HCV and achieved SVR. The liver recipient, despite developing severe acute graft rejection and undergoing intense immunosuppression with T cell-depleting antibodies, did not become HCV RNA-positive with a follow up period of 8 months. The recipient was HCV seronegative before transplant, but became HCV seropositive immediately posttransplant. The antibodies were undetectable after 97 days, in keeping with a passive antibody transmission or B lymphocyte transmission with the graft.

conclusionsTo the best of our knowledge, this is the first reported case of an HCV seropositive liver allograft transplanted into an HCV-negative recipient who subsequently received intense immunosuppression. This case, therefore, is an encouraging and novel step in liver transplantation, and demonstrates that SVR may be closer to a true "cure" of HCV in the donor population and that, even in circumstances of very potent immunosuppression in the recipient, this SVR is sustained.

Identifiers

PMID29707618
PMCPMC5912017
OpenAlexW2790072378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.